The tweet was deleted by the author.
But we saved everything 🙂.
Arcturus Therapeutics has introduced its next-generation lipid delivery system, LUNAR 2.0, while providing an update on its program targeting OTC deficiency.
The announcement was included in a company presentation made in September, which also covered advancements in its mRNA therapeutic pipeline. Arcturus Therapeutics continues to focus on innovations for rare disease treatments, highlighting ongoing progress in the development of solutions for metabolic and genetic disorders.
View post on X Loading...
Arcturus Therapeutics previously presented new findings from its ARCT-810 mRNA therapy for OTC deficiency at SSIEM 2026, highlighting dietary and biochemical data in patients treated with the drug. Additional details on the study are available in the company’s update on dietary and biochemical outcomes for ARCT-810. These disclosures demonstrate Arcturus’s ongoing commitment to addressing rare metabolic conditions.